Real-World Eylea HD Data Presented at ARVO

Initial data from nearly 40,000 patients demonstrate early visual improvements and reduced injection frequency.

By: Jim Gallagher, senior managing editor

Retinal Physician May 8, 2025

5 Key Takeaways

1

Real-world data from nearly 40,000 patients indicate Eylea HD may reduce injection frequency while improving vision in nAMD and DME.
2

Switching to Eylea HD extended injection intervals by 2 to 3 weeks for previously treated DME patients.
3

Treatment-naïve DME patients with poor baseline vision improved by 7.9 to 9.6 letters within 90 days of starting Eylea HD.
4

Post-loading phase injection intervals for treatment-naïve patients averaged 63 to 69 days, suggesting potential for longer dosing schedules.
5

Common adverse events with Eylea HD included cataract and increased intraocular pressure, with no new safety signals found.

Jim Gallagher

Senior Managing Editor

Affiliations: Glaucoma Physician

Specialties: Ophthalmology

Bio: Jim Gallagher is Senior Managing Editor of Glaucoma Physician, a publication dedicated to developments in glaucoma diagnosis, treatment, and patient care. In his editorial role he writes, curates, and oversees content spanning clinical updates, conference coverage, and emerging innovations in glaucoma science and care. Though not a clinician himself, Gallagher plays a pivotal role in translating complex ophthalmologic research and practice trends to an audience of glaucoma specialists, contributing features, editorials, and news reporting. He frequently collaborates with glaucoma physicians, researchers, and thought leaders to highlight advances in therapies, surgical devices, and care delivery.

PentaVision

Retinal Physician

Real-World Eylea HD Data Presented at ARVO

5 Key Takeaways

1

2

3

4

5

Recommendations